This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Puma Biotech (PBYI) Q3 Earnings Beat, Revenues Lag Estimates
by Zacks Equity Research
Puma Biotech's (PBYI) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens the full-year revenue guidance.
Agios (AGIO) Reports Narrower-Than-Expected Q3 Loss, Lags Sales
by Zacks Equity Research
Agios' (AGIO) Q3 earnings beat estimates, but sales miss the same.
Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss
by Zacks Equity Research
Karuna's (KRTX) third-quarter 2023 earnings miss estimates. The company did not record any sales during the quarter.
Allogene's (ALLO) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the same. Management reiterated its previously issued financial guidance for 2023.
Puma Biotech (PBYI) Tops Q3 Earnings Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 13.33% and 3.16%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
PBYI or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
Puma Biotech (PBYI) Loses -18.62% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Puma Biotech (PBYI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
PBYI vs. AMGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. AMGN: Which Stock Is the Better Value Option?
Puma's (PBYI) Alisertib Gets FDA's Orphan Drug Tag for SCLC
by Zacks Equity Research
Puma's (PBYI) alisertib receives the Orphan Drug designation from the FDA for treating patients with small cell lung cancer.
Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 42.86% and 6.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
PBYI vs. GMAB: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PBYI vs. GMAB: Which Stock Is the Better Value Option?
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND, MESO and PBYI well amid volatility.
Bluebird (BLUE) Down 26% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PBYI or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
by Zacks Equity Research
Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.
PBYI vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. TECH: Which Stock Is the Better Value Option?
Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y
by Zacks Equity Research
Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 550% and 6.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of -35.09% and 7.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Q4 Loss Wider Than Expected, Sales Top
by Zacks Equity Research
Puma Biotechnology's (PBYI) Q4 2022 loss is wider than estimates, Revenues beat the same.
CERT vs. PBYI: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CERT vs. PBYI: Which Stock Is the Better Value Option?
Puma Biotech (PBYI)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
Puma Biotechnology, Inc. (PBYI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Puma Biotechnology (PBYI) Stock a Solid Choice Right Now?
by Zacks Equity Research
Puma Biotechnology (PBYI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.